Skip to main content
Fig. 4 | Clinical Epigenetics

Fig. 4

From: Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract

Fig. 4

Receiver operating characteristic (ROC) curves and area under the curve (AUC) values for SHOX2, SEPT9, and the combined biomarker panel, based on the sum of PMR values, in plasma samples. AUC—SHOX2 = 0.691 [95% CI 0.554–0.828]; AUC-SEPT9 = 0.699 [95% CI 0.561–0.837]; AUC-Panel = 0.752 [95% CI 0.631–0.873]

Back to article page